Real-time endobronchial ultrasound images are crucial for the accurate placement of the needle in peribronchial lung tumors and lymph nodes for diagnostic sampling. Beyond its role as a diagnostic tool, ultrasound-guided bronchoscopy can also aid the delivery of anti-cancer agents intratumorally, enabling diagnosis, staging, and treatment to occur within the same anesthesia, reducing the patient's burden. However, determining drug retention and distribution
in situ
remains challenging, albeit pivotal in assessing the success or failure of the therapeutic intervention. We hypothesized that ultrasound images acquired by the bronchoscope during the injection can provide qualitative and quantitative real-time information about drug transport. As a proof-of-concept, we retrospectively analyzed 13 videos of intratumoral cisplatin injections in advanced non-small cell lung cancers. We identified the injection and performed quantitative analysis through image processing and segmentation algorithms and mathematical models in 5 of them. We were able to infer the unlikeliness of a laminar flow through interstitial pores in favor of the emergence of tissue fractures. These data imply that the structural integrity of the tumor is a critical determinant of the ultimate distribution of an intratumorally delivered agent.
Rationale Direct intratumoral delivery of cisplatin via endobronchial ultrasound-transbronchial needle injections (EBUS-TBNI) is a novel approach for treatment of advanced-stage non-small cell lung cancer (NSCLC), including in combination with immunotherapy. Prior studies have demonstrated high rates of response in the treated volume. While it is established that direct cell death may act as an effective immunoadjuvant, even sublethal doses of cisplatin may activate the immune response. Specifically, there is evidence that cisplatin may alter programmed death ligand-1 (PDL1) expression. As the combination of direct intratumoral cisplatin and immunotherapy continues to be evaluated, it is critical to determine the cellular impact of direct intratumoral cisplatin. Methods Under an IRB approved protocol, patients undergoing clinicallyindicated weekly treatments with EBUS-TBNI cisplatin consented to additional biopsies. Prior to delivery of cisplatin, needle aspiration was performed at each procedure. Cells were stained with UV blue to determine live/dead percentages and quantitated via flow cytometry. Cells were stained for PDL1 in the live and dead cell gates for each cell type. Isotype controls were performed for each antibody stain. Analysis was performed using FlowJo software. All statistical analyses were performed using STATA. P values less than or equal to 0.05 were considered statistically significant. Results Three patients completed 4 treatments with EBUS-TBNI cisplatin. One of these patients was on immunotherapy with a PDL1 checkpoint inhibitor (nivolumab). Treatment over 4 weeks resulted in a significant increase in cell death, with an average of a 27% increase in cell death (P=0.049). There was an increase in the percentage of CD45-/ CD66+ cells in both the live and dead gates (22%, P=0.046). For CD45-/CD326+ cells (representing tumor epithelial cells) in the dead gate, there was a 23% decrease in PDL1+ cells with treatment over four weeks. In the live gate, there was an average decrease of 12% in PDL1+ cells for the two patients who did not receive immunotherapy. For the patient on nivolumab, there was an increase in PDL1+ cells of 26%. Conclusion EBUS-TBNI cisplatin results in significant tumor cell death and an increase in CD45-/CD66+ cells, which may represent granulocytes related to an inflammatory response, or myeloid-derived suppressor cells. With ongoing treatment, live CD45-/CD326+ cells were increasingly PDL1 negative for patients not on immunotherapy. Interestingly, for the patient on nivolumab, there was an increase in live CD45-/CD326+ PDL1 positive cells. Further analysis with larger number of patients will be necessary to better characterize this response.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.